Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Heart Failure
NCT03027960Phase 1Completed
- Sponsor
- Yale University
- Start
- Jun 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of empagliflozin in heart failure (HF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Yale University. Primary endpoint: Urine sodium concentrations via ion selective electrodes at 36 days. Started Jun 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03027960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03027960.